DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

DBV Technologies S.A. (NASDAQ:DBVT) has received an average rating of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $38.65.

DBVT has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Guggenheim reiterated a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a report on Friday, March 27th. Finally, Citizens Jmp increased their target price on shares of DBV Technologies from $45.00 to $47.00 and gave the company a “market outperform” rating in a report on Friday, March 27th.

Institutional Trading of DBV Technologies

Several institutional investors and hedge funds have recently made changes to their positions in DBVT. Artisan Partners Limited Partnership raised its holdings in shares of DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after purchasing an additional 3,257,135 shares during the last quarter. Siren L.L.C. purchased a new stake in DBV Technologies during the fourth quarter worth about $35,606,000. Vivo Capital LLC increased its holdings in DBV Technologies by 133.4% during the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock worth $47,189,000 after buying an additional 1,407,120 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies during the second quarter worth about $9,659,000. Finally, MPM Bioimpact LLC purchased a new stake in DBV Technologies during the second quarter worth about $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Price Performance

Shares of DBVT stock opened at $19.64 on Thursday. The firm has a 50-day moving average of $20.97 and a 200-day moving average of $18.65. The company has a market cap of $1.09 billion, a P/E ratio of -3.76 and a beta of -0.94. DBV Technologies has a one year low of $7.53 and a one year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Saturday, February 14th. The company reported ($1.15) EPS for the quarter. The firm had revenue of $0.65 million during the quarter. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 189.17%. As a group, research analysts expect that DBV Technologies will post -0.82 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.